MC
DNA icon

Meteora Capital’s Ginkgo Bioworks DNA Stock Holding History

Meteora Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,100
Closed -$184K – 396
2025
Q4 		$184K Sell
22,100
-380
-2% -$4.09K 0.02% 195
2025
Q3 		$328K Sell
22,480
-29,320
-57% -$351K 0.03% 143
2025
Q2 		$583K Buy
51,800
+29,800
+135% +$231K 0.11% 80
2025
Q1 		$125K Sell
22,000
-23,502
-52% -$239K 0.04% 91
2024
Q4 		$447K Sell
45,502
-464,450
-91% -$3.98M 0.15% 82
2024
Q3 		$4.16M Buy
509,952
+477,447
+1,469% +$4.78M 1.15% 29
2024
Q2 		$435K Buy
+32,505
New +$970K 0.08% 134

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meteora Capital's DNA Position: Q1 2026 in Review

Meteora Capital sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 22,100 shares — an estimated $184K sold.

Meteora Capital first reported a position in DNA in Q2 2024 and held it in 7 quarters. The position peaked at $4.16M in Q3 2024. 175 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Meteora Capital reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
  • Meteora Capital sold 22,100 Ginkgo Bioworks shares in Q1 2026, an estimated $184K.
  • Meteora Capital first reported a position in Ginkgo Bioworks in Q2 2024 and held it in 7 quarters.
  • Meteora Capital's Ginkgo Bioworks position peaked at $4.16M in Q3 2024.
  • 175 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Meteora Capital's 13F filing for Q1 2026, filed 15 May 2026.